|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.14 USD | -5.30% |
|
-1.99% | -21.67% |
| 09/07 | IRenix Medical, Inc., Tarsus Pharmaceuticals, Inc. - M&A Call | |
| 09/07 | Tarsus Pharmaceuticals Buys iRenix Medical | MT |
| Market Cap | 2.76B 2.41B 2.23B 2.06B 3.91B 263B 3.97B 26.66B 10.45B 129B 10.36B 10.14B 448B | P/E 2026 * |
-77.6x | P/E 2027 * | 21x |
|---|---|---|---|---|---|
| Enterprise Value | 2.76B 2.41B 2.23B 2.06B 3.91B 263B 3.97B 26.66B 10.45B 129B 10.36B 10.14B 448B | EV / Sales 2026 * |
3.96x | EV / Sales 2027 * | 3.04x |
| Free-Float |
96.94% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Tarsus Pharmaceuticals, Inc.
| 1 day | -5.30% | ||
| 1 week | -1.99% | ||
| Current month | +1.91% | ||
| 1 month | +4.21% | ||
| 3 months | -11.44% | ||
| 6 months | -16.56% | ||
| Current year | -21.67% |
| 1 week | 61.71 |  | 72.5 |
| 1 month | 56.51 | | 72.5 |
| Current year | 56 | | 83.92 |
| 1 year | 38.51 | | 85.25 |
| 3 years | 12.57 | | 85.25 |
| 5 years | 10.8 | | 85.25 |
| 10 years | 10.8 | | 85.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 48 | 01/09/2018 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 64 | 24/04/2023 |
| Chief Tech/Sci/R&D Officer | 47 | 04/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Bobak Azamian
CHM | Chairman | 48 | 02/12/2022 |
| Director/Board Member | 71 | 01/12/2019 | |
Bill Link
BRD | Director/Board Member | 80 | 01/01/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/06 | Free | Director | 6,254 | 0.0145% | ||
| 25/06 | Free | Director | 6,254 | 0.0145% | ||
| 25/06 | Free | Director | 7,463 | 0.0173% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.30% | -1.99% | +55.34% | +264.22% | 2.91B | |
| +0.76% | +2.09% | +20.88% | -3.54% | 67.44B | |
| +0.52% | -5.52% | +46.80% | +219.12% | 53.98B | |
| -2.79% | +32.50% | +32.50% | +32.50% | 41.77B | |
| -1.83% | +1.13% | -49.18% | -53.36% | 41.15B | |
| -0.72% | -7.96% | +49.53% | -27.69% | 29.58B | |
| +3.74% | -4.01% | +133.49% | -35.59% | 29.28B | |
| +1.07% | +1.42% | +72.47% | +90.95% | 23.43B | |
| +4.57% | +3.25% | +12.96% | +204.71% | 19.11B | |
| +1.14% | -0.17% | +68.83% | +135.40% | 16.82B | |
| Average | +0.15% | +0.65% | +44.36% | +82.67% | 32.55B | |
| Weighted average by Cap. | +0.30% | -0.94% | +36.58% | +55.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 698M 610M 563M 521M 988M 66.59B 1B 6.74B 2.64B 32.7B 2.62B 2.56B 113B | 906M 793M 731M 677M 1.28B 86.52B 1.31B 8.76B 3.43B 42.49B 3.4B 3.33B 147B |
| Net income | -38.53M -33.7M -31.08M -28.76M -54.58M -3.68B -55.49M -372M -146M -1.81B -145M -141M -6.26B | 157M 137M 126M 117M 222M 14.94B 225M 1.51B 593M 7.34B 588M 575M 25.41B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/07/26 | USD 64.14 | -5.30% | 2,168,792 |
| 08/07/26 | USD 67.73 | -4.00% | 1,330,643 |
| 07/07/26 | USD 70.55 | +5.22% | 1,685,124 |
| 06/07/26 | USD 67.05 | +2.46% | 1,458,724 |
| 02/07/26 | USD 65.44 | +7.47% | 1,785,690 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TARS Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
